COCP READ THE FULL COCP RESEARCH REPORT Business Update Norovirus Challenge Study to Commence in 4Q25 Cocrystal Pharma, Inc. ...

Preparations are underway for a Phase 1b norovirus challenge study to evaluate our potent, oral antiviral candidate CDI-988 as a prophylaxis and ...

Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later ...

All CDI-988 doses, ranging from 100 mg to 1200 mg, in the Phase 1 study were well toleratedCompany expects to initiate Phase 1b study with CDI-988 in norovirus-infected healthy subjects later this ...

Get the latest Cocrystal Pharma Inc (8CC.SG) stock news and headlines to help you in your trading and investment decisions.

CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain The Company’s virology study further confirmed the previous structural and in vitro ...

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses ...

Detailed price information for Cocrystal Pharma Inc (COCP-Q) from The Globe and Mail including charting and trades.

BOTHELL, Wash., May 28, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that management will participate in a fireside chat during ...

BOTHELL, Wash., May 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2025, and provides ...

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs May 15, 2025 8:00 AM ET Cocrystal Pharma, Inc. (COCP) ...